GENEXI Biotech Accelerator announces Advisory Board

“Our mission is to establish a foundation and become the industry leader in biotech drug development driven by scientific vision and clinical acumen, and supported by a distinguished clinical development team and advisors in order to research and manufacture medicine that is used in the treatment of various diseases”. – GENEXI Foundation.

In September 2017, Alexey Zhelyaskov founded GENEXI Biotech Accelerator, which operates as a Platform and a Foundation focusing on Hi-Tech Bio&Med research and drug development. GENEXI assembled an impressive Advisory Board and Core Team which, among others, include professional experts in biomedicine, digital health, life sciences, pharmaceuticals, downstream chemical processing, agriculture and bioservices. GENEXI will provide research, business development and marketing support to promising biotech projects to ensure their further development.

In Q3 2017, GENEXI announced the launch of sustainable innovative ecosystem that brings transparency into biotech sector through blockchain technology. The project’s leaders reckon that in the field of healthcare, the application of this business model will be more than justified. GENEXI ecosystem is a digital space with a complex of high tech solutions, through which manufacturers, distributors and retailers can interact with each other by minimizing fraudulent activities of participants. The project’s primary purpose is combine its scientific, medical and project evaluation and development expertise to select the most promising arising solutions and studies in the process of continuous market monitoring and research.

GENEXI Foundation is an organization employing a wide range of high-level innovative research scientists, who have dedicated themselves to an alternative industry different from the conventional life-science paths. GENEXI support specialists who provide manual heuristic analysis for most detailed venture assessment and prognosis. GENEXI has established partnership with leading research labs, institutes and medical advisors to select the most promising projects with the highest expected return rates: Dr. Sergey Turin – Ph.D, leading Russian chemist, Dr. Phyllis Martin – PhD, American microbiologist, Dr. Brenda Oppert – PhD, Dr. Alexander Novoselov – Phd, biotech analyst, Russian State Genetic Research Institute, Russian Toxicology and Hygiene Research Institute, American Ministry of Agriculture Research Center.

Dr. Sergey Turin, Head of Medical Research

With than 35 years of medical experience, Sergey is an author of multiple research papers on topics including bioorganic and protein chemistry. His career started in 1982 at State Research Institute of Genetics and Selection of Industrial Microorganisms of the National Research Centre, where he studied the chemical structure of the bendotoxin protein. After the graduation he started a project on biopreparation of bendotoxin with extended spectrum of insecticidal activity, successfully collaborating with the US Department of Agriculture. In 2008, he founded an innovative company BIOS whose main purpose was to create a new product on the basis of bacteriorhodopsin protein, which resulted in the development of a new highly effective medicine to treat skin diseases.

“We get feedbacks from patients who find themselves desperate and on the brink of death and a particular drug can extend their lives. This pushes scientists and physicians to full-scale studies, financed by various investment funds and institutions. As a doctor, I would like to see more highly effective drugs that do not have a wide range of side effects. However, this is constrained by a complex system of clinical trials, the improvement of which, in my opinion, is necessary”.

Alexander Novoselov, Biotech Analyst

Alexander is a Director of the Moscow Society of Dermatologists. He joined Genexi in 2016, following five years with Russian Dermatology Academic Research Centre and over a decade of working for global health, development and public sector organisations. Alexander holds a Masters degree in Medicine.

“Traditional medicine has played out its role. Biotech is currently the most progressive field, both in general and in medicine in particular. GENEXI’s mission is to lengthen patients’ active lives by applying cutting-edge, clinically proven products. We will soon be treating systematic diseases that require us to alter the genome, address DNA-level defects, reorder amino acids… That is our future”.

Roel Wolfer, Advisor

Roel has more than 20 years of international experience on business and technology in retail and transactional banking, payments and bank cards, retailing, management consulting, IT and venture capital. He holds MSc in Economics from Maastricht University and an executive degree in innovation from the Haas School of Business at UC Berkeley. He is also the Chief Operating Officer at Qoin, where he focuses on policy, monetary design, legal advice and tokenomics development.

Malcolm Tan, Advisor

Malcolm Tan is an established Singaporean lawyer-entrepreneur with extensive experience in construction, telecommunications, engineering, retail, IT, and financial industries. Malcolm is skilled in litigation, corporate law, and M&A. He previously held legal counsel positions in both global and regional capacities across the Asia-Pacific region, MENA, and North America. Malcolm has been involved in corporate advisory and corporate finance field, in deals from angel to VC and PE, and also Pre-IPO and IPO deals.

“Blockchain is an ideal business solution to overcome counterfeiting. Primarily through serialisation, and more stringent checks and a possibility of removal of the middleman through smart-contracts and provenance. GENEXI should aim to cater for Asian community attending conferences in China, Japan, Korea, as well as in Hong Kong and Singapore. The sticky money is institutions and retail crowd. Institutional capital is your most strategic capital and it will help pave the way to a secondary offering.

Anti Danilevski, Crowdfunding Advisor

As a founder of KICKICO platform, he leads the biggest Russian crowdfunding community as well as other online communities. Anti has been involved in the blockchain community since 2014 and brings his 11 years of experience in crowdfunding, online community-building into GENEXI.

“When I first met Alexey Zhelyaskov, GENEXI’s founder, I was impressed by his ambitious ideas and his risky but innovative business-model. He presented me their first product and I decided to give it to my friend who had been struggling with psoriasis. The feedback I received from my companion was largely positive: product did work and did not cause any side effects. GENEXI’s products meets people’s need – and that keeps GEN tokens in-demand. The utility token can continue to evolve over time. Their value is defined by the audience and can remain relatively unchanged, so their value in the market will continue to increase. GENEXI takes a model that has proven itself and applies it to a niche in great need of a solution.  As long as something is useful, it will be around, and it will be valuable. I think the main challenge of GENEXI is not only in developing its Foundation and raising funds but also in saving the world of its presence”.

From May 1 to July 31, 2018, GENEXI Biotech Accelerator will hold an ICO. During  this period GENEXI plans to collect from 20 to 70 million dollars. 60% of funds will be allocated to the grant program, the rest – to the infrastructure system development, testing, and launching, and the project development. Upon reaching a hardcap of 70 million dollars, GENEXI will allocate 3 grants for a total of 100,000 dollars on simplified terms to biotech labs and companies who will express the wish to become partners with GENEXI Biotech Accelerator before the end of the ICO.

The investors are eligible for bonuses. The period from May 1 to May 31 will be the most beneficial for tokenholders: in this case, the bonus will be 20%, from June 1 to June 14 – 17%, from June 15 to June 28 – 9%, from June 29 to July 12 5%, and then 2% until the end of the initial coin offering.

Project Links and Resources

The post GENEXI Biotech Accelerator announces Advisory Board appeared first on Bitcoin Garden.

Komentar

Posting Komentar

Postingan populer dari blog ini

Blockchain Supply Chain Forum will be held on January 10th in Hong Kong

Gambar
The concept of a blockchain – a distributed, tamper-proof and time-stamped database of transactions that can be managed without intermediaries – is highly attractive in the supply chain domain, and the industry has launched a number of proof-of-concept initiatives. However, awareness of how blockchains work and what they can accomplish for supply chain is still relatively low. The lack of knowledge is exacerbated by the fast pace at which the technology is evolving. A success Blockchain Supply Chain Forum was held on October 24th in Shanghai, professional blockchain organizer EventLinker and Global Supply Chain Council will organize the Blockchain Supply Chain Forum on January 10th in Hong Kong, it is the forum connecting blockchain experts, supply chain and logistics decision makers and tech innovators. This intimate gathering will explore how companies are investigating the use and deployment of the technology to help their supply chains in China. Organizer: EventLinker EventLin
Baca selengkapnya

Transformation of education in post-industrial society

Gambar
Education has always been an expensive privilege; and the education sector has always been one of the most conservative. People chose profession once in their life and did not change it until retirement. Usually education meant studying at a university; self-taught people were rare. However, in the post-industrial society changes in the shape, sense and affordability of education finally began. According to Alvin Toffler, a well-known US sociologist, the emergence of the post-industrial society is a consequence of the intellectual revolution. The possession of knowledge and information will replace financial capital as the biggest value. Development of innovations, empowered by the most educated, will become the most important sector of economy. It means that high-quality affordable education will become even more important than now. The last time when the global education experienced a serious transformation was at the very beginning of the 21st century when the wide access to the I
Baca selengkapnya

After GDPR effect? In A Post Cookie World, Blockchain Is Rising

Gambar
The European General Data Protection Regulation (GDPR) was rolled out in May this year. It introduced far-reaching implications for companies which process personal data related to EU citizens. Even those far outside the EU could not fail to notice this change. Email inboxes were overflowing with opt-out reminders. Cookie banners now obscure many websites, forcing users to agree to a privacy policy so that they can browse the content on the site. Although the GDPR document itself clocks in at 88 pages, the majority of what it covers can be summed up in one word — consent. If companies are processing personal data, it must be done with the explicit, informed consent of the individual. For some forms of marketing, such as email subscriber lists, this involved minimal changes. Individuals already have to take the active step of providing their email addresses, and usually it is pretty clear why they are asked to do so. However, for the digital advertising industry, consent is far less
Baca selengkapnya